Sato T, Osumi H, Shinozaki E, Ooki A, et al. Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer. Anticancer Res 2021;41:3905-3915.
PMID: 34281853